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A B S T R A C T
While many cases of streptococcal infection are due to Lanceﬁeld groups A and B, there has been a rise in
reported cases of infections due to group G streptococcus. We present a case of an individual with a
hematologic malignancy who developed myositis secondary to group G streptococcus, with no clearly
identiﬁable source of infection. The patient was managed with antibiotic therapy rather than surgical
intervention due to high surgical risk related to severe thrombocytopenia. Targeted antibiotics initiated
early in the course of disease may prevent the need for surgical intervention. Early diagnosis and
treatment are critical to avoid the high morbidity and mortality of life-threatening infections caused by
group G streptococcus.
ã 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Introduction
Epidemiologically, most streptococcal infections fall under
Lanceﬁeld groups A and B, however few cases have been reported
from groups C and G, with a variety of clinical manifestations [1,2].
Lanceﬁeld groups C and G (GCS and GGS) colonize normal skin and
oral ﬂora as well as the genitourinary and gastrointestinal tracts,
and infections caused by GCS and GGS are typically opportunistic
[3,4]. GCS and GGS are b-hemolytic streptococci, classiﬁed as
Streptococcus dysgalactiae subspecies equismilis (SDSE), and
possess pyogenic abilities, making them virulent [5]. Although
SDSE is distinct from S. pyogenes, a substantial overlap of clinical
syndromes and virulence factors exists [5,6].
Myositis, deﬁned as degeneration and inﬂammation of muscle
tissue without abscess formation, is distinctly different from
necrotizing fasciitis, which involves subcutaneous tissue and skin,
to the level of the fascia [7,8]. Streptococcal myositis is a rare
infection which carries a high mortality rate if intervention is
delayed [7]. The majority of streptococcal myositis cases described
in the literature are a result of group A strep (GAS) infections, with
an identiﬁed or presumable source [3,7,9]. We report a case of
myositis caused by group G streptococcal (GGS) infection, with no
clearly identiﬁable source in an immunocompromised individual
with a hematologic malignancy.
Case presentation
A 57year old male with an 8month history of biopsy conﬁrmed
myeloproliferative neoplasm presented with 4days of fever and
generalized body aches. He complained of nausea and fatigue
along with bilateral calf pain. He reported no sore throat or oral
ulcers, or any trauma to his legs. Risk factors for infection included
recent dental extraction, and exposure to grandchildren who had
developed upper respiratory tract infections after travel toMexico.
He had received only supportive platelet transfusions while
awaiting future bone marrow transplantation.
On examination, temperature was 104.1 F, pulse 158 beats per
minute and blood pressurewas 96/64mmHg. Cardiac examination
revealed tachycardia without a murmur, and tenderness to
palpation of both calves without edema or lesions; Homans’ sign
was negative. The remainder of the physical examination was
unremarkable, including oral, pulmonary, skin and lymphatic
systems.
Laboratory data revealed a white cell count of 20.0K/uL with
38% bands, a platelet count of 23K/uL, and a creatine kinase (CK) of
453(iU)/L. Deep vein thrombosis was excluded via venous Doppler
examination of both legs. Blood and urine cultureswere drawn and
the patient was started on empiric vancomycin, imipenem-
cilastatin and gentamicin for presumed sepsis.
On day 2 of admission, the patient complained ofworsening calf
tenderness. Physical examination revealed development of bullae
on the lower extremities with swelling and decreased range of
motion. Emergent lower extremity CT scans showed indistinct* Corresponding author.
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margins of calf musculaturewith no soft tissue gas. Due to concern
for compartment syndrome, compartment pressures were moni-
tored serially and peaked as high as 29mmHg. CK peaked at 11,607
(iU)/L, consistent with rhabdomyolysis. Blood cultures grew Gram
positive cocci in chains and further resulted with group G
streptococcus. Due to thrombocytopenia, IV antibiotics were
continued without surgical intervention. Antibiotics were nar-
rowed to ampicillin with clindamycin.
Subsequently the patient’s condition improved with antibiotic
therapy, and additional imaging and blood culture results
conﬁrmed resolving group G streptococcal myositis, rhabdomyol-
ysis and early compartment syndrome. Further workup, including
trans-thoracic echocardiogram and throat culture, was negative.
Discussion
Most reported cases of streptococcal myositis are linked to
Lanceﬁeld groups A and B, with a rising incidence of reported cases
duetogroupGstreptococcus. These infectionscanbesevereandlife-
threatening, especially when they occur in patients with underlying
immunocompromising conditions, such as malignancy or HIV [1].
GGS shares virulence factors with GAS, leading to a similar
spectrum of disease [3]. Adhesins help enable bacterial invasion
into the bloodstream via colonization of the basement membrane
and have been demonstrated in GCS and GGS [5]. M proteins are
encoded by the emm gene, and are a major virulence factor of
b-hemolytic streptococci, likely playing a role in infectivity by
allowing resistance to phagocytes and adherence to epithelial cells
[5,10]. The ability of GGS to enter the bloodstream coupledwith the
ability of the M protein to interfere with the coagulation and
complement cascades [5] may then lead to inﬂammatory changes
in the skin and soft tissues, resulting in myositis and early
compartment syndrome.
Pyrogenic exotoxins such as speS, previously identiﬁed in GGS,
may act as superantigens cross-linking T cell receptors and MHCII,
thereby upregulating pro-inﬂammatory cytokines leading to septic
shock [5,7]. Horizontal gene transfer among the different groups of
streptococci appears to enhance bacterial virulence and survival,
and has been widely demonstrated in GGS species [1,9,11]. We
believe that the virulence of GGS combined with the patient’s
susceptibility for infection in the setting of malignancy likely
increased his propensity for severe illness.
Myeloproliferative neoplasm (MPN) is a chronic myeloid
disorder; however this patient’s bone marrow and cytology were
not diagnostic of one of the classic MPN’s, such as chronic myeloid
leukemia, polycythemia vera or essential thrombocytosis. His bone
marrow analysis was negative for BCR-ABL and JAK2 mutations.
Subsequent biopsy was suggestive but not diagnostic of early
primary myeloﬁbrosis.
Patients with primary hematologic malignancies and resulting
immunocompromised states are at increased risk for infection.
Hematologic cancers predispose patients to infection via bone
marrow involvement and T-cell dysfunction [12]. Although cases
have been described in patients linking hematologic cancers and
bacteremia [13], to our knowledge this is the ﬁrst case report of a
patient with myeloproliferative neoplasm, streptococcal bacter-
emia, and myositis.
Primary treatment of this patient consisted of antibiotic
management and expectant monitoring of compartment pressures
and imaging,which differs fromoptimal therapy as described in the
literature. Fasciotomy was not performed given severe thrombocy-
topenia and high surgical risk. In most cases of myositis, early
surgical debridement is the cornerstone of treatment as antibiotics
alone are often not effective [2,14]. Antibiotic therapy should be
initiated early with the use of penicillins and clindamycin.
Clindamycin,a lincosamideantibioticandbacterialproteinsynthesis
inhibitor, has been shown to inhibit streptococcal virulence factors
including the M protein at the ribosomal level [3,9,14].
Intravenous immunoglobulins have been shown to help in
neutralizing antibodies in streptococcal infections, however this
approach was not used for our patient [7,14,15]. Presently, there is
insufﬁcient data to provide strong support for this treatment
approach; in our patient’s case, given that he showed clinical
improvement with targeted antibiotic therapy, immunoglobulins
were not used.
Conclusions
In summary, we present the case of a 57 year old male with
altered immunologic defenses. Although no clear source of
streptococcal infection could be identiﬁed in this patient, we
hypothesize that his underlying myeloproliferative neoplasm
increased his risk for developing myositis once infected.
Myositis caused by streptococcal infection can be rapidly fatal
with a high morbidity and mortality and one must remain vigilant
to diagnose this condition to prevent an adverse outcome. Early
detection is paramount to survival, and therefore, it is critically
important to have a high clinical suspicion for streptococcal
myositis. Imaging that does not indicate soft tissue gas or abscess
becomes less suggestive of necrotizing fasciitis or pyomyositis, and
myositis should therefore be suspected. Prompt treatment with
antibiotics and surgical debridement, if appropriate, remain the
key to therapy. The early use of targeted antibiotics led to
improvement and eventual resolution of our patient’s clinical
condition, which obviated the need for surgical intervention.
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